Subscribe free

HPB & Spleen ·

Anti-PD-1 Therapy Boosts Survival in High-Risk HCC Patients

Postoperative anti-PD-1 therapy significantly enhances overall survival and recurrence-free survival in hepatocellular carcinoma (HCC) patients, particularly those with vessels encapsulating tumor clusters (VETC), a marker of aggressive disease. Among 388 patients studied, those receiving the therapy showed improved outcomes compared to untreated counterparts, while VETC status emerged as a crucial prognostic biomarker. This study underscores the importance of tailoring immunotherapy based on disease aggressiveness.

Observational Study by Zhao X, Peng Y, Hu A and Jiang S in BMC Surg

© 2025. The Author(s).

read the whole article in BMC Surg

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in HPB & Spleen.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in HPB & Spleen

The latest stitches

Surg Endosc6 Nov 2026

A new cut for robotic liver surgery

A close-to-open cutting method was used for robotic liver resection, with no bile leaks and shorter hospital stays than after laparoscopy.

Surg Endosc6 Nov 2026

Robotic bile duct stone surgery: fewer complications

Removing large common bile duct stones with a robot rather than laparoscopically was linked to fewer complications and shorter hospital stays, at a higher cost, in a study from one Chinese hospital.

All papers in HPB & Spleen →